Direct Thrombin Inhibitor (Parenterally Administered Anticoagulant)
Argatroban Monohydrate
Brand names: Exembol, Novastan
Adult dose
Dose: Heparin-induced thrombocytopenia (HIT): 2 micrograms/kg/min IV, adjusted to aPTT 1.5–3× normal; max 10 micrograms/kg/min. Hepatic impairment: start at 0.5 micrograms/kg/min
Route: Intravenous continuous infusion
Frequency: Continuous infusion; titrate to aPTT
Clinical pearls
- Direct thrombin inhibitor — inhibits both free and clot-bound thrombin without requiring antithrombin as cofactor (unlike heparin)
- Indicated when heparin is contraindicated, specifically HIT (heparin-induced thrombocytopenia with or without thrombosis)
- No reversal agent available — manage bleeding with supportive care; half-life ~40–50 min
- BSH HIT Guidelines: argatroban and bivalirudin are non-heparin anticoagulant alternatives for HIT; fondaparinux also used
- Argatroban elevates INR — use chromogenic factor X assay (or target INR >4) when transitioning to warfarin
- NICE does not have a specific TA — used per BSH/BCSH HIT guidelines and local formulary
Contraindications
- Active major bleeding
- Severe hepatic impairment (mainly hepatically eliminated — major dose reduction required)
Side effects
- Haemorrhage (dose-dependent — most serious)
- Fever
- Nausea
- Hypotension
- Elevated LFTs
Interactions
- Other anticoagulants — additive bleeding risk; avoid concomitant use
- Warfarin transition: argatroban prolongs PT/INR — use a chromogenic factor X assay or specialist protocol for warfarin transition
- Thrombolytics — additive bleeding risk
Monitoring
- aPTT every 2 hours until stable, then every 4–6 hours
- Platelet count (monitoring for HIT resolution)
- Signs of thrombosis or haemorrhage
- LFTs (hepatic elimination — dose-adjust in hepatic impairment)
- INR (if warfarin overlap — see pearl above)
Reference: BNF; BSH Guidelines on diagnosis and management of HIT (2012 updated 2019); BCSH argatroban guidelines; https://bnf.nice.org.uk/drugs/argatroban-monohydrate/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- 4Ts Score for Heparin-Induced Thrombocytopenia · Thrombocytopenia
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO